next gen tirzepatide GLP-TZ Retatrutide, Eli Lilly’s Next-Gen Obesity

"It helped to realize this is part of it - not failure, just fluctuation." - u/FlexWithIt In these stories, the return of food noise isnt always a setback

MASH resolution without worsening of fibrosis: 2.4 mg dose: 47% of participants (vs 14% placebo) 4.8 mg dose: 62% of participants (vs 14% placebo) 6.0 mg dose: 43% of participants (vs 14% placebo) Liver fat reduction of at least 30%: 2.4 mg dose: 63% of participants 4.8 mg dose: 67% of participants 6.0 mg dose: 57% of participants Placebo: 14% of participants Fibrosis improvement by at least one stage: Survodutide groups: 34-36% Placebo: 22% The percentage change from baseline in liver fat content after 48 weeks was a staggering 62% reduction in the 6.0 mg group, compared to just 5.7% in the placebo group

Retatrutide 2026 Phase 3 Results: What the Data Shows The TRIUMPH Phase 3 program is what turned retatrutide from a promising early-stage molecule into headline news

L-carnitine as an ergogenic aid for patients with chronic obstructive pulmonary disease submitted to whole-body and respiratory muscle training programs

SURMOUNT-5 head-to-head: tirzepatide delivered 20.2% weight loss vs 13.7% for semaglutide at 72 weeks

Aggressive tumor cells are phenotypically plastic, sharing properties with embryonic progenitors